MA15.08 Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naïve Metastatic NSCLC

Benefit for patients with metastatic NSCLC from treatment with front-line immune checkpoint inhibitor (ICI) ± chemotherapy is limited by primary and secondary ICI resistance. Tumor-infiltrating lymphocyte (TIL) cell therapy has produced tumor regression in patients with extensively pretreated metastatic NSCLC (Schoenfeld SITC 2021; Creelan Nat Med 2021). Integration of TIL cell therapy in front-line regimens may improve long-term benefit. We report the first efficacy and safety data for LN-145 autologous TIL cell therapy in combination with pembrolizumab in patients with ICI-naïve metastatic NSCLC.